-
By Gerald Burstyn |
March 26, 2012
Tevye the milkman.
He’s not the first person who comes to mind for the average value investor, but according to value guru Vitaliy Katsenelson, we can learn a lot from Tevye.
-
By Kenneth Silber |
October 1, 2009
Biotech has long been a high-risk, high-reward industry. It is an industry in which numerous firms, including many small-caps and start-ups, intensively research possible...
-
By Janet Levaux, AdvisorOne |
September 1, 2007
While recalls on some goods made in China have been grabbing headlines, certain mutual funds that focus on China remain untainted by the scandals. The...
-
By James Picerno |
November 1, 2006
"I spend 90 percent of my time on 5 percent of my clients' portfolios," says Dale Stevens, president of Grasswood Partners Inc., a Malibu, Calif....
-
By Staff Writer |
August 18, 2005
The rising popularity of exchange-traded funds (ETFs) has opened the door to other new investment products offered as alternatives to mutual funds. Among these are...
-
By Staff Writer |
February 10, 2003
Jan. 31, 2003 -- By any measure, biotech stocks suffered a disastrous year in 2002. Mutual funds investing in biotech tracked by Standard & Poor's...
-
By Staff Writer |
December 1, 2000
Faraz Naqvi, Manager and M.D., uses his varied exp
